Clinical bottom line
Joint contractures in systemic sclerosis (SSc) represent a challenging and often refractory manifestation that significantly impairs hand function and quality of life. Emerging therapies, including autologous stem cell transplantation and novel antifibrotic agents, show promise in improving joint mobility and reducing fibrosis, but evidence remains limited and largely from small case series or early-phase studies. Serial casting and physical therapy remain important adjuncts for managing contractures. Clinicians should consider a multidisciplinary approach tailored to disease severity and patient-specific factors while awaiting more robust clinical trial data.
What the evidence shows
Joint contractures in SSc arise primarily from skin fibrosis and periarticular tissue involvement, leading to fixed flexion deformities, especially in the digits (Serup et al., 2009). Measurement techniques for contractures have been standardized, facilitating assessment of therapeutic interventions (Serup et al., 2009). Traditional management includes physical therapy and splinting; however, refractory cases require more intensive approaches.
Autologous stem cell transplantation (ASCT) has demonstrated potential in reversing skin fibrosis and improving joint contractures in aggressive diffuse SSc. Anandacoomarasamy et al. (2006) reported resolution of skin thickening and joint contractures following ASCT in a small cohort, suggesting durable benefit in severe disease refractory to conventional immunosuppression. While promising, ASCT carries significant risks and is reserved for select patients.
Novel antifibrotic therapies targeting pathways implicated in SSc fibrosis are under investigation. Bouffette et al. (unpublished data) highlight emerging agents aiming to modulate fibrotic cascades, though clinical data specifically addressing joint contractures remain sparse.
A recent study by Uğurlu et al. (2026) evaluated serial casting for proximal interphalangeal joint contractures in SSc patients, demonstrating improved range of motion and functional outcomes with minimal adverse effects. This non-pharmacologic intervention may be a valuable adjunct in refractory contractures.
Case reports and series (Kay et al., 2011; Bolster et al., 2011) underscore the heterogeneity of contracture presentation and the need for individualized treatment plans. These reports emphasize the importance of early recognition and intervention to prevent irreversible deformity.
Caveats and uncertainty
The evidence base for novel therapies in refractory joint contractures in SSc is limited by small sample sizes, lack of randomized controlled trials, and heterogeneity in patient populations and outcome measures. ASCT, while effective in some cases, is associated with significant morbidity and mortality risks, limiting its applicability.
The efficacy of antifibrotic agents specifically for joint contractures remains largely hypothetical, with most data extrapolated from skin fibrosis studies. Long-term safety and optimal timing of these therapies require further elucidation.
Non-pharmacologic interventions such as serial casting show promise but need validation in larger, controlled studies with standardized protocols. The durability of improvements and impact on daily functioning remain to be fully characterized.
How this may change practice
Clinicians managing SSc patients with refractory joint contractures should maintain a high index of suspicion for early contracture development and implement multidisciplinary care involving rheumatologists, hand therapists, and rehabilitation specialists.
Emerging evidence supports consideration of ASCT in carefully selected patients with aggressive diffuse SSc and disabling contractures unresponsive to standard therapies, balancing potential benefits against procedural risks.
Incorporation of serial casting and structured physical therapy may enhance joint mobility and function, representing a low-risk adjunctive strategy.
Ongoing clinical trials of novel antifibrotic agents warrant clinician awareness, as these may expand therapeutic options in the near future. Until more definitive data are available, treatment decisions should be individualized, emphasizing symptom management and functional preservation.